Connection

VARSHA V GANDHI to Pyrimidines

This is a "connection" page, showing publications VARSHA V GANDHI has written about Pyrimidines.
Connection Strength

1.661
  1. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018 11 22; 132(21):2249-2259.
    View in: PubMed
    Score: 0.272
  2. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3734-3743.
    View in: PubMed
    Score: 0.241
  3. Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia. Leuk Lymphoma. 2016; 57(6):1494-7.
    View in: PubMed
    Score: 0.223
  4. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015 Aug 15; 21(16):3705-15.
    View in: PubMed
    Score: 0.214
  5. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2013 Dec 10; 6:92.
    View in: PubMed
    Score: 0.195
  6. Development and characterization of prototypes for in?vitro and in?vivo mouse models of ibrutinib-resistant CLL. Blood Adv. 2021 08 24; 5(16):3134-3146.
    View in: PubMed
    Score: 0.083
  7. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
    View in: PubMed
    Score: 0.071
  8. Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'. Leuk Lymphoma. 2019 07; 60(7):1603-1605.
    View in: PubMed
    Score: 0.070
  9. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018 04; 32(4):920-930.
    View in: PubMed
    Score: 0.064
  10. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015 Sep; 29(9):1811-22.
    View in: PubMed
    Score: 0.054
  11. Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood. 2015 Jan 08; 125(2):407-10.
    View in: PubMed
    Score: 0.053
  12. Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma. 2012 Oct; 53(10):2024-32.
    View in: PubMed
    Score: 0.044
  13. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 02; 119(5):1182-9.
    View in: PubMed
    Score: 0.043
  14. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply. N Engl J Med. 2019 08 22; 381(8):789.
    View in: PubMed
    Score: 0.018
  15. Guanosine acts intracellularly to initiate apoptosis in NB4 cells: A role for nucleoside transport. Leuk Lymphoma. 2007 Sep; 48(9):1816-27.
    View in: PubMed
    Score: 0.008
  16. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006 Nov 15; 66(22):10959-66.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.